Granite Investment Partners LLC Lowers Stock Holdings in Establishment Labs Holdings Inc. $ESTA

Granite Investment Partners LLC cut its holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 30.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 161,017 shares of the company’s stock after selling 71,683 shares during the period. Granite Investment Partners LLC’s holdings in Establishment Labs were worth $6,600,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. CenterBook Partners LP acquired a new stake in shares of Establishment Labs during the second quarter worth $16,204,000. Viking Global Investors LP purchased a new position in Establishment Labs during the second quarter worth about $14,669,000. Woodson Capital Management LP boosted its stake in Establishment Labs by 113.3% in the 3rd quarter. Woodson Capital Management LP now owns 480,000 shares of the company’s stock worth $19,675,000 after buying an additional 255,000 shares during the last quarter. Pier Capital LLC purchased a new stake in Establishment Labs in the 2nd quarter valued at about $10,777,000. Finally, Soleus Capital Management L.P. purchased a new stake in Establishment Labs in the 2nd quarter valued at about $9,050,000. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Analyst Upgrades and Downgrades

ESTA has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research report on Monday, December 29th. Canaccord Genuity Group lifted their price target on shares of Establishment Labs from $72.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Needham & Company LLC reissued a “buy” rating and set a $84.00 price objective on shares of Establishment Labs in a research note on Monday, January 12th. JPMorgan Chase & Co. increased their target price on Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 17th. Finally, Citigroup boosted their price target on Establishment Labs from $62.00 to $75.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $78.86.

Establishment Labs Price Performance

Establishment Labs stock opened at $76.00 on Monday. The firm has a fifty day moving average of $70.82 and a 200-day moving average of $57.14. Establishment Labs Holdings Inc. has a 52-week low of $26.56 and a 52-week high of $78.24. The company has a quick ratio of 2.10, a current ratio of 3.33 and a debt-to-equity ratio of 15.06. The firm has a market capitalization of $2.21 billion, a P/E ratio of -26.76 and a beta of 0.99.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.